Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study
| العنوان: | Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study |
|---|---|
| المؤلفون: | A. Rauscher, Jacques Barbet, Caroline Bodet-Milin, Evelyne Cerato, Mickaël Bourgeois, A. David, Céline Bossard, Yann Touchefeu, Clément Bailly, Françoise Kraeber-Bodéré, T. Eugène, Damien Masson, Eric Frampas, David M. Goldenberg, Thomas Carlier, Alain Faivre-Chauvet, Robert M. Sharkey, Caroline Rousseau |
| المساهمون: | Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service de Radiologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Pathologie [CHU Nantes], Unité de Pharmacie [ICO, Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Délégation à la Recherche Clinique et à l'Enovation [Nantes] ((DRCI)), Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Immunomedics Inc. [Morris Plains, NJ, USA], IBC Pharmaceuticals Inc [Morris Plains, NJ, USA], ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), Bernardo, Elizabeth, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes) |
| المصدر: | European Journal of Nuclear Medicine and Molecular Imaging European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2021, 48, pp.874-882. ⟨10.1007/s00259-020-04989-3⟩ European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, pp.874-882. ⟨10.1007/s00259-020-04989-3⟩ |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Endoscopic ultrasound, Bispecific antibody, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gallium Radioisotopes, Pilot Projects, Colorectal cancer metastases, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Heterocyclic Compounds, 1-Ring, 0302 clinical medicine, Carcinoembryonic antigen, [SDV.CAN] Life Sciences [q-bio]/Cancer, Fluorodeoxyglucose F18, Biopsy, medicine, Humans, Radiology, Nuclear Medicine and imaging, Immuno-positron emission tomography, Fluorodeoxyglucose, medicine.diagnostic_test, biology, Bispecific monoclonal antibody, business.industry, Gallium-68, Antibodies, Monoclonal, Magnetic resonance imaging, General Medicine, 3. Good health, Carcinoembryonic Antigen, Positron emission tomography, 030220 oncology & carcinogenesis, Positron-Emission Tomography, biology.protein, Nuclear medicine, business, Colorectal Neoplasms, Pretargeted radioimmunoimaging, Oligopeptides, Emission computed tomography, medicine.drug |
| الوصف: | International audience; Introduction: This pilot study evaluated the imaging performance of pretargeted immunological positron emission tomography (immuno-PET) using an anti-carcinoembryonic antigen (CEA) recombinant bispecific monoclonal antibody (BsMAb), TF2 and the [68Ga]Ga-labelled HSG peptide, IMP288, in patients with metastatic colorectal carcinoma (CRC).Patients and methods: Patients requiring diagnostic workup of CRC metastases or in case of elevated CEA for surveillance were prospectively studied. They had to present with elevated CEA serum titre or positive CEA tumour staining by immunohistochemistry of a previous biopsy or surgical specimen. All patients underwent endoscopic ultrasound (EUS), chest-abdominal-pelvic computed tomography (CT), abdominal magnetic resonance imaging (MRI) and positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET). For immuno-PET, patients received intravenously 120 nmol of TF2 followed 30 h later by 150 MBq of [68Ga]Ga-labelled IMP288, both I.V. The gold standard was histology and imaging after 6-month follow-up.Results: Eleven patients were included. No adverse effects were reported after BsMAb and peptide injections. In a per-patient analysis, immuno-PET was positive in 9/11 patients. On a per-lesion analysis, 12 of 14 lesions were positive with immuno-PET. Median SUVmax, MTV and TLG were 7.65 [3.98-13.94, SD 3.37], 8.63 cm3 [1.98-46.64; SD 14.83] and 37.90 cm3 [8.07-127.5; SD 43.47] respectively for immuno-PET lesions. Based on a per-lesion analysis, the sensitivity, specificity, positive-predictive value and negative-predictive value were, respectively, 82%, 25%, 82% and 25% for the combination of EUS/CT/MRI; 76%, 67%, 87% and 33% for FDG-PET; and 88%, 100%, 100% and 67% for immuno-PET. Immuno-PET had an impact on management in 2 patients.Conclusion: This pilot study showed that pretargeted immuno-PET using anti-CEA/anti-IMP288 BsMAb and a [68Ga]Ga-labelled hapten was safe and feasible, with promising diagnostic performance. |
| وصف الملف: | application/pdf |
| تدمد: | 1619-7089 1619-7070 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76792ca63585a1ccaac63b570c284af8Test https://pubmed.ncbi.nlm.nih.gov/32820369Test |
| حقوق: | EMBARGO |
| رقم الانضمام: | edsair.doi.dedup.....76792ca63585a1ccaac63b570c284af8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16197089 16197070 |
|---|